Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study

1094^ Background: In the AVADO study, BV + D confirmed the clinical benefit of combining BV with taxane-based first-line chemotherapy. This analysis evaluated the safety and efficacy of BV + D in pts aged ≥65 years. Methods: Pts with HER2-negative, inoperable, LR or mBC received BV 7.5 or 15mg/kg + D 100mg/m2 or placebo (PL) + D. Pts had no prior chemotherapy for advanced disease, no CNS metastases, ECOG PS 0–1, adequate LVEF. D was administered q3w up to nine cycles, BV/PL q3w until disease progression/unacceptable toxicity. Results: BV + D significantly increased PFS compared with PL + D (BV 7.5: HR = 0.69, p=0.004; BV 15: HR = 0.61, p=0.0001) (Table) (median follow-up 10.2 months). BV significantly increased overall response rate (ORR) compared with PL. In the 127 (17.3%) pts aged ≥65 years, pts had a similar treatment benefit compared to the entire study population. Generally, BV had limited additional impact on the known side effects of D. No grade ≥3 GI perforation, wound-healing complications, CHF ...